Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Clinical Rheumatology
Published in: Clinical Rheumatology 9/2015

01-09-2015 | Original Article

Transcriptional network profile on synovial fluid T cells in psoriatic arthritis

Authors: Ugo Fiocco, Veronica Martini, Benedetta Accordi, Francesco Caso, Luisa Costa, Francesca Oliviero, Anna Scanu, Monica Facco, Daniele Boso, Mariele Gatto, Mara Felicetti, Paola Frallonardo, Roberta Ramonda, Lucia Piva, Renato Zambello, Carlo Agostini, Raffaele Scarpa, Giuseppe Basso, Gianpietro Semenzato, Jean-Michel Dayer, Leonardo Punzi, Andrea Doria

Published in: Clinical Rheumatology | Issue 9/2015

Login to get access

Abstract

The objective of the study was to quantify the transcriptional profile, as the main T cell lineage-transcription factors on synovial fluid (SF) T cells, in relation to SF cytokines and T cell frequencies (%) of psoriatic arthritis (PsA) patients. Reverse phase protein array was employed to identify interleukin (IL)-23Rp19-, FOXP3- and related orphan receptor gamma T (RORγt)- protein and Janus associated tyrosine kinases 1 (JAK1), signal transducer and activator and transcription 1 (STAT1), STAT3 and STAT5 phosphoproteins in total T cell lysates from SF of PsA patients. IL-1β, IL-2, IL-6, IL-21 and interferon (INF)-γ were measured using a multiplex bead immunoassay in SF from PsA patients and peripheral blood (PB) from healthy controls (HC). Frequencies of CD4+CD25−, CD4+CD25high FOXP3+ and CD4+CD25high CD127low Treg, and either mean fluorescence intensity (MFI) of FOXP3+ on CD4+ Treg or MFI of classic IL-6 receptor (IL-6R) α expression on CD4+CD25− helper/effector T cells (Th/eff) and Treg cells, were quantified in SF of PsA patients and in PB from HC by flow cytometry (FC). In PsA SF samples, IL-2, IL-21 and IFN-γ were not detectable, whereas IL-6 and IL-1β levels were higher than in SF of non-inflammatory osteoarthritis patients. Higher levels of IL-23R-, FOXP3- and RORγt proteins and JAK1, STAT1, STAT3 and STAT5 were found in total T cells from SF of PsA patients compared with PB from HC. Direct correlations between JAK1 Y1022/Y1023 and STAT5 Y694, and STAT3 Y705 and IL6, were found in SF of PsA patients. Increased proportion of CD4+CD25high FOXP3+ and CD4+CD25high CD127low Treg cells and brighter MFI of IL-6Rα were observed both on CD4+CD25high- and CD4+CD25− T cells in PsA SF. The study showed a distinctive JAK1/STAT3/STAT5 transcriptional network on T cells in the joint microenvironment, outlining the interplay of IL-6, IL-23, IL-1β and γC cytokines in the polarization and plasticity of Th17 and Treg cells, which might participate in the perpetuation of joint inflammation in PsA patients.
Literature
1.
van Kuijk AW, Reinders-Blankert P, Smeets TJ, Dijkmans BA, Tak PP (2006) Detailed analysis of the cell infiltrate and the expression of mediators of synovial inflammation and joint destruction in the synovium of patients with psoriatic arthritis: implications for treatment. Ann Rheum Dis 65:1551–7PubMedCentralCrossRefPubMed
2.
Fiocco U, Sfriso P, Oliviero F, Roux-Lombard P, Scagliori E, Cozzi L, Lunardi F, Calabrese F, Vezzù M, Dainese S, Molena B, Scanu A, Nardacchione R, Rubaltelli L, Dayer JM, Punzi L (2010) Synovial effusion and synovial fluid biomarkers in psoriatic arthritis to assess intraarticular tumor necrosis factor-α blockade in the knee joint. Arthritis Res Ther 12:R148PubMedCentralCrossRefPubMed
3.
Goodman WA, Levine AD, Massari JV, Sugiyama H, McCormick TS, Cooper KD (2009) IL-6 signaling in psoriasis prevents immune suppression by regulatory T cells. J Immunol 183:3170–6PubMedCentralCrossRefPubMed
4.
Evans CM, Jenner RG (2013) Transcription factor interplay in T helper cell differentiation. Brief Funct Genom 12:499–511CrossRef
5.
O’Shea JJ, Lahesmaa R, Vahedi G, Laurence A, Kanno Y (2011) Genomic views of STAT function in CD4? T helper cell differentiation. Nat Rev Immunol 11:239–50PubMedCentralCrossRefPubMed
6.
Kanno Y, Vahedi G, Hirahara K, Singleton K, O’Shea JJ (2012) Transcriptional and epigenetic control of T helper cell specification: molecular mechanisms underlying commitment and plasticity. Annu Rev Immunol 230:707–31CrossRef
7.
Sakaguchi S, Ono M, Setoguchi R, Yagi H, Hori S, Fehervari Z, Shimizu J, Takahashi T, Nomura T (2006) Foxp3+ CD25+ CD4+ natural regulatory T cells in dominant self-tolerance and autoimmune disease. Immunol Rev 212:8–27CrossRefPubMed
8.
Bettelli E, Carrier Y, Gao W, Korn T, Strom TB, Oukka M, Weiner HL, Kuchroo VK (2006) Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 441:235–8CrossRefPubMed
9.
Josefowicz SZ, Lu LF, Rudensky AY (2012) Regulatory T cells: mechanisms of differentiation and function. Annu Rev Immunol 30:531–64CrossRefPubMed
10.
11.
Sakaguchi S, Vignali DA, Rudensky AY, Niec RE, Waldmann H (2013) The plasticity and stability of regulatory T cells. Nat Rev Immunol 13:461–7CrossRefPubMed
12.
Heinrich PC, Behrmann I, Haan S, Hermanns HM, Müller-Newen G, Schaper F (2003) Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem J 374:1–20PubMedCentralCrossRefPubMed
13.
Guschin D, Rogers N, Briscoe J, Witthuhn B, Watling D, Horn F, Pellegrini S, Yasukawa K, Heinrich P, Stark GR et al (1995) A major role for the protein tyrosine kinase JAK1 in the JAK/STAT signal transduction pathway in response to interleukin-6. EMBO J 14:1421–9PubMedCentralPubMed
14.
Ghoreschi K, Laurence A, Yang XP, Tato CM, McGeachy MJ, Konkel JE, Ramos HL, Wei L, Davidson TS, Bouladoux N, Grainger JR, Chen Q, Kanno Y, Watford WT, Sun HW, Eberl G, Shevach EM, Belkaid Y, Cua DJ, Chen W, O’Shea JJ (2010) Generation of pathogenic T (H) 17 cells in the absence of TGF-b signalling. Nature 467:967–71PubMedCentralCrossRefPubMed
15.
Parham C, Chirica M, Timans J, Vaisberg E, Travis M, Cheung J, Pflanz S, Zhang R, Singh KP, Vega F et al (2002) A receptor for the heterodimeric cytokine IL-23 is composed of IL-12Rbeta1 and a novel cytokine receptor subunit, IL-23R. J Immunol 168:5699–5708CrossRefPubMed
16.
McGeachy MJ, Chen Y, Tato CM, Laurence A, Joyce-Shaikh B, Blumenschein WM, McClanahan TK, O’Shea JJ, Cua DJ (2009) The interleukin 23 receptor is essential for the terminal differentiation of interleukin 17-producing effector T helper cells in vivo. Nat Immunol 10:314–24PubMedCentralCrossRefPubMed
17.
Annunziato F, Romagnani S (2010) The transient nature of the Th17 phenotype. Eur J Immunol 40:3312–6CrossRefPubMed
18.
Wehrens EJ, Prakken BJ, van Wijk F (2013) T cells out of control-impaired immune regulation in the inflamed joint. Nat Rev Rheumatol 9:34–42CrossRefPubMed
19.
Cao D, van Vollenhoven R, Klareskog L, Trollmo C, Malmström V (2004) CD25brightCD4+ regulatory T cells are enriched in inflamed joints of patients with chronic rheumatic disease. Arthritis Res Ther 6:R335–46PubMedCentralCrossRefPubMed
20.
Sugiyama H, Gyulai R, Toichi E, Garaczi E, Shimada S, Stevens SR, McCormick TS, Cooper KD (2005) Dysfunctional blood and target tissue CD4+CD25high regulatory T cells in psoriasis: mechanism underlying unrestrained pathogenic effector T cell proliferation. J Immunol 174:164–73PubMedCentralCrossRefPubMed
21.
Goodman WA, Young AB, McCormick TS, Cooper KD, Levine AD (2011) Stat3 phosphorylation mediates resistance of primary human T cells to regulatory T cell suppression. J Immunol 186:3336–3345PubMedCentralCrossRefPubMed
22.
Herrath J, Müller M, Amoudruz P, Janson P, Michaëlsson J, Larsson PT, Trollmo C, Raghavan S, Malmström V (2011) The inflammatory milieu in the rheumatic joint reduces regulatory T-cell function. Eur J Immunol 41:2279–90CrossRefPubMed
23.
Appel H, Wu P, Scheer R, Kedor C, Sawitzki B, Thiel A, Radbruch A, Sieper J, Syrbe U (2011) Synovial and peripheral blood CD4+FoxP3+ T cells in spondyloarthritis. J Rheumatol 38:2445–51CrossRefPubMed
24.
Bovenschen HJ, van de Kerkhof PC, van Erp PE, Woestenenk R, Joosten I, Koenen HJ (2011) Foxp3+ regulatory T cells of psoriasis patients easily differentiate into IL-17A-producing cells and are found in lesional skin. J Invest Dermatol 131:1853–1860CrossRefPubMed
25.
Koenen HJ, Smeets RL, Vink PM, van Rijssen E, Boots AM, Joosten I (2008) Human CD25highFoxp3pos regulatory T cells differentiate into IL-17-producing cells. Blood 112:2340–2352CrossRefPubMed
26.
Komatsu N, Okamoto K, Sawa S, Nakashima T, Oh-hora M, Kodama T, Tanaka S, Bluestone JA, Takayanagi H (2014) Pathogenic conversion of Foxp3+ T cells into TH17 cells in autoimmune arthritis. Nat Med 20:62–8CrossRefPubMed
27.
Fiocco U, Accordi B, Martini V, Oliviero F, Facco M, Cabrelle A, Piva L, Molena B, Caso F, Costa L, Scanu A, Pagnin E, Atteno M, Scarpa R, Basso G, Semenzato G, Punzi L, Doria A, Dayer JM (2014) JAK/STAT/PKCδ molecular pathways in synovial fluid T lymphocytes reflect the in vivo T helper-17 expansion in psoriatic arthritis. Immunol Res 58:61–9CrossRefPubMed
28.
Seddiki N, Santner-Nanan B, Martinson J, Zaunders J, Sasson S, Landay A, Solomon M, Selby W, Alexander SI, Nanan R, Kelleher A, de St F, Groth B (2006) Expression of interleukin (IL)-2 and IL-7 receptors discriminates between human regulatory and activated T cells. J Exp Med 203:1693–700PubMedCentralCrossRefPubMed
29.
Zola H, Flego L (1992) Expression of interleukin-6 receptor on blood lymphocytes without in vitro activation. Immunology 76:338–40PubMedCentralPubMed
30.
Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H, CASPAR Study Group (2006) Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 54:2665–73CrossRefPubMed
31.
Accordi B, Espina V, Giordan M, VanMeter A, Milani G, Galla L, Ruzzene M, Sciro M, Trentin L, De Maria R, te Kronnie G, Petricoin E, Liotta L, Basso G (2010) Functional protein network activation mapping reveals new potential molecular drug targets for poor prognosis pediatric BCP-ALL. PLoS One 5, e13552PubMedCentralCrossRefPubMed
32.
Benham H, Norris P, Goodall J, Wechalekar MD, FitzGerald O, Szentpetery A, Smith M, Thomas R, Gaston H (2013) Th17 and Th22 cells in psoriatic arthritis and psoriasis. Arthritis Res Ther 15:R136PubMedCentralCrossRefPubMed
33.
Fujitani Y, Hibi M, Fukada T, Takahashi-Tezuka M, Yoshida H, Yamaguchi T et al (1997) An alternative pathway for STAT activation that is mediated by the direct interaction between JAK and STAT. Oncogene 14:751–61CrossRefPubMed
34.
35.
Kryczek I, Wei S, Vatan L, Escara-Wilke J, Szeliga W, Keller ET, Zou W (2007) Cutting edge: opposite effects of IL-1 and IL-2 on the regulation of IL-17+ T cell pool IL-1 subverts IL-2-mediated suppression. J Immunol 179:1423–6CrossRefPubMed
36.
Oberg HH, Wesch D, Grüssel S, Rose-John S, Kabelitz D (2006) Differential expression of CD126 and CD130 mediates different STAT-3 phosphorylation in CD4 + CD25- and CD25high regulatory T cells. Int Immunol 18:555–563CrossRefPubMed
37.
Anderson AE, Pratt AG, Sedhom MA, Doran JP, Routledge C, Hargreaves B, Brown PM, Lê Cao KA, Isaacs JD, Thomas R (2015) IL-6-driven STAT signalling in circulating CD4+ lymphocytes is a marker for early anticitrullinated peptide antibody-negative rheumatoid arthritis. Ann Rheum Dis. doi:10.​1136/​annrheumdis-2014-205850
38.
Mease P, Gottlieb AB, Berman A, Drescher E, Xing J, Banerjee S , Wong R (2014) A phase IIb, randomized, double-blind, placebo-controlled, dose-ranging, multicenter study to evaluate the efficacy and safety of clazakizumab, an anti-IL-6 monoclonal antibody, in adults with active psoriatic arthritis. arthritis & rheumatology. vol. 66. 111 River St, Hoboken 07030–5774, NJ USA: Wiley-Blackwell. ACR abstract n. 952
39.
Johnston JA, Bacon CM, Finbloom DS, Rees RC, Kaplan D, Shibuya K, Ortaldo JR, Gupta S, Chen YQ, Giri JD et al (1995) Tyrosine phosphorylation and activation of STAT5, STAT3, and Janus kinases by interleukins 2 and 15. Proc Natl Acad Sci U S A 92:8705–8709CrossRefPubMed
40.
Maeshima K, Yamaoka K, Kubo S, Nakano K, Iwata S, Saito K, Ohishi M, Miyahara H, Tanaka S, Ishii K, Yoshimatsu H, Tanaka Y (2012) The JAK inhibitor tofacitinib regulates synovitis through inhibition of interferon-γ and interleukin-17 production by human CD4+ T cells. Arthritis Rheum 64:1790–8CrossRefPubMed
41.
Boyle DL, Soma K, Hodge J, Kavanaugh A, Mandel D, Mease P, Shurmur R, Singhal AK, Wei N, Rosengren S, Kaplan I, Krishnaswami S, Luo Z, Bradley J, Firestein GS (2015) The JAK inhibitor tofacitinib suppresses synovial JAK1-STAT signalling in rheumatoid arthritis. Ann Rheum Dis 74(6):1311–6PubMedCentralCrossRefPubMed
42.
Mease PJ, Armstrong AW (2014) Managing patients with psoriatic disease: the diagnosis and pharmacologic treatment of psoriatic arthritis in patients with psoriasis. Drugs 74:423–41PubMedCentralCrossRefPubMed
43.
Hansen RB, Kavanaugh A (2014) Novel treatments with small molecules in psoriatic arthritis. Curr Rheumatol Rep 16:443CrossRefPubMed
44.
Ryder LR, Bartels EM, Woetmann A, Madsen HO, Odum N, Bliddal H, Danneskiold-Samsøe B, Ribel-Madsen S, Ryder LP (2012) FoxP3 mRNA splice forms in synovial CD4+ T cells in rheumatoid arthritis and psoriatic arthritis. APMIS 120:387–96CrossRefPubMed
45.
Partsch G, Steiner G, Leeb BF, Dunky A, Broll H, Smolen JS (1997) Highly increased levels of tumor necrosis factor-α and other proinflammatory cytokines in psoriatic arthritis synovial fluid. J Rheumatol 24:518–23PubMed
46.
Burchill MA, Yang J, Vogtenhuber C, Blazar BR, Farrar MA (2007) IL-2 receptor beta-dependent STAT5 activation is required for the development of Foxp3+ regulatory T cells. J Immunol 178(1):280–90CrossRefPubMed
47.
Yang XP, Ghoreschi K, Steward-Tharp SM, Rodriguez-Canales J, Zhu J, Grainger JR et al (2011) Opposing regulation of the locus encoding IL-17 through direct, reciprocal actions of STAT3 and STAT5. Nat Immunol 12:247–54PubMedCentralCrossRefPubMed
48.
Tormo AJ, Letellier MC, Sharma M, Elson G, Crabé S, Gauchat JF (2012) IL-6 activates STAT5 in T cells. Cytokine 60:575–82CrossRefPubMed
49.
Zhang L, Yang XQ, Cheng J, Hui RS, Gao TW (2010) Increased Th17 cells are accompanied by FoxP3(+) Treg cell accumulation and correlated with psoriasis disease severity. Clin Immunol 135:108–17CrossRefPubMed
50.
Ghoreschi K, Jesson MI, Li X, Lee JL, Ghosh S, Alsup JW, Warner JD, Tanaka M, Steward-Tharp SM, Gadina M, Thomas CJ, Minnerly JC, Storer CE, LaBranche TP, Radi ZA, Dowty ME, Head RD, Meyer DM, Kishore N, O’Shea JJ (2011) Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550). J Immunol 186:4234–43PubMedCentralCrossRefPubMed
51.
Basu R, Whitley SK, Bhaumik S, Zindl CL, Schoeb TR, Benveniste EN, Pear WS, Hatton RD, Weaver CT (2015) IL-1 signaling modulates activation of STAT transcription factors to antagonize retinoic acid signaling and control the T (H) 17 cell-iT (reg) cell balance. Nat Immunol 16:286–295CrossRefPubMed
52.
Nish SA, Schenten D, Wunderlich FT, Pope SD, Gao Y, Hoshi N, Yu S, Yan X, Lee HK, Pasman L, Brodsky I, Yordy B, Zhao H, Brüning J, Medzhitov R (2014) T cell-intrinsic role of IL-6 signaling in primary and memory responses. Elife (Cambridge) 19;3:e01949
53.
Li L, Kim J, Boussiotis VA (2010) IL-1β-mediated signals preferentially drive conversion of regulatory T cells but not conventional T cells into IL-17-producing cells. J Immunol 185:4148–53PubMedCentralCrossRefPubMed
54.
Park JS, Lee J, Lim MA, Kim EK, Kim SM, Ryu JG, Lee JH, Kwok SK, Park KS, Kim HY, Park SH, Cho ML (2014) JAK2-STAT3 blockade by AG490 suppresses autoimmune arthritis in mice via reciprocal regulation of regulatory T Cells and Th17 cells. J Immunol 192:4417–24CrossRefPubMed
55.
Höfer T, Krichevsky O, Altan-Bonnet G (2012) Competition for IL-2 between regulatory and effector T cells to chisel immune responses. Front Immunol 3:268PubMedCentralCrossRefPubMed
56.
Passerini L, Allan SE, Battaglia M, Di Nunzio S, Alstad AN, Levings MK et al (2008) STAT5-signaling cytokines regulate the expression of FOXP3 in CD4 + CD25+ regulatory T cells and CD41CD25- effector T cells. Int Immunol 20:421–431CrossRefPubMed
57.
Benito-Miguel M, García-Carmona Y, Balsa A, Pérez de Ayala C, Cobo-Ibáñez T, Martín-Mola E, Miranda-Carús ME (2009) A dual action of rheumatoid arthritis synovial fibroblast IL-15 expression on the equilibrium between CD4 + CD25+ regulatory T cells and CD4 + CD25- responder T cells. J Immunol 183:8268–79CrossRefPubMed
58.
Pandiyan P, Yang XP, Saravanamuthu SS, Zheng L, Ishihara S, O’Shea JJ, Lenardo MJ (2012) The role of IL-15 in activating STAT5 and fine-tuning IL-17A production in CD4 T lymphocytes. J Immunol 189:4237–46PubMedCentralCrossRefPubMed
Metadata
Title
Transcriptional network profile on synovial fluid T cells in psoriatic arthritis
Authors
Ugo Fiocco
Veronica Martini
Benedetta Accordi
Francesco Caso
Luisa Costa
Francesca Oliviero
Anna Scanu
Monica Facco
Daniele Boso
Mariele Gatto
Mara Felicetti
Paola Frallonardo
Roberta Ramonda
Lucia Piva
Renato Zambello
Carlo Agostini
Raffaele Scarpa
Giuseppe Basso
Gianpietro Semenzato
Jean-Michel Dayer
Leonardo Punzi
Andrea Doria
Publication date
01-09-2015
Publisher
Springer London
Published in
Clinical Rheumatology / Issue 9/2015
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-015-3002-2

Other articles of this Issue 9/2015

Clinical Rheumatology 9/2015 Go to the issue

Original Article

Use of dual-energy computed tomography for the evaluation of calcinosis in patients with systemic sclerosis

Original Article

Clinical and laboratory factors associated with interstitial lung disease in rheumatoid arthritis

Brief Report

Distinct profiles of myositis-specific autoantibodies in Chinese and Japanese patients with polymyositis/dermatomyositis

Letter to the Editor

IL-17, a potential therapeutic target for Sjögren’s syndrome?

Case Based Review

Rheumatologic manifestations of the “MonoMAC” syndrome. a systematic review

Original Article

Prognostic factors in a cohort of antisynthetase syndrome (ASS): serologic profile is associated with mortality in patients with interstitial lung disease (ILD)
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits